Literature DB >> 11369902

Terbinafine-induced subacute cutaneous lupus erythematosus.

G Bonsmann1, M Schiller, T A Luger, S Ständer.   

Abstract

BACKGROUND: Recently, the induction of subacute cutaneous lupus erythematosus (SCLE) and exacerbation of systemic lupus erythematosus by terbinafine have been reported.
OBJECTIVE: We describe 4 cases of SCLE, one associated with chilblain lupus, which occurred during therapy with oral terbinafine for onychomycosis.
METHODS: Of 21 consecutive patients with SCLE attending the outpatient dermatology department at Muenster University clinic during a 1-year period, 4 patients with terbinafine-induced SCLE were seen. Patients were examined fully and photographed; histologic findings as well as serologic and follow-up data were evaluated.
RESULTS: In addition to high titers of antinuclear antibodies (ANA) with a homogeneous pattern, anti-Ro(SS-A) antibodies were present; in 3 of 4 women, anti-La(SS-B) antibodies were also found. All patients had anti-histone antibodies as in drug-induced lupus and showed the characteristic genetic association of SCLE with the HLA-B8,DR3 haplotype; moreover, in 2 cases, HLA-DR2 was also present. After discontinuation of terbinafine, ANA titers decreased; anti-histone antibodies also became undetectable within 4(1/2) months in 3 patients concomitant with subsidence of the SCLE eruption in all patients.
CONCLUSION: Terbinafine is a drug that appears to infrequently induce SCLE with high titers of ANAs and anti-histone antibodies in genetically susceptible persons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369902     DOI: 10.1067/mjd.2001.114565

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  [Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification].

Authors:  A Kuhn; K Gensch; S Ständer; G Bonsmann
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

3.  [Drug-induced subacute cutaneous lupus erythematosus: repeated occurrence following treatment with terbinafine].

Authors:  G Wagner; M M Sachse
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

4.  [Facial pigmentation following therapy with terbinafine].

Authors:  K Breuer; B Völker; R Gutzmer; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

Review 5.  [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].

Authors:  P Mayser
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

6.  [Terbinafine-induced subacute cutaneous lupus erythematosus. Case report and review of the literature].

Authors:  T Matthes; M Hagedorn
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

Review 7.  Skin manifestations of drug reactions.

Authors:  James Q Del Rosso
Journal:  Curr Allergy Asthma Rep       Date:  2002-07       Impact factor: 4.919

8.  Methimazole-induced bullous systemic lupus erythematosus: a case report.

Authors:  Ji-Yeon Seo; Hee-Jin Byun; Kwang-Hyun Cho; Eun Bong Lee
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

9.  Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids.

Authors:  Agnieszka Kalińska-Bienias; Cezary Kowalewski; Katarzyna Woźniak
Journal:  Postepy Dermatol Alergol       Date:  2013-08-27       Impact factor: 1.837

10.  Proton pump inhibitor-induced subacute cutaneous lupus erythematosus.

Authors:  L H Sandholdt; R Laurinaviciene; A Bygum
Journal:  Br J Dermatol       Date:  2014-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.